Melanoma New Diagnosis
Solid Tumors Melanoma New Diagnosis
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
- Ages: 0 Years to 21 Years
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adul ...More
Contact Us
To learn more about available clinical trials related to solid tumors, contact us at cancer@cchmc.org or 513-636-2799.
Related Studies
- Retinoblastoma New Diagnosis
- Retinoblastoma Relapse / Refractory
- Neurofibromatosis Sarcoma New Diagnosis
- Neurofibromatosis Sarcoma Relapse / Refractory
- Neurofibromatosis NF2
- Neurofibromatosis Plexiform Neurofibroma
- Neurofibromatosis OPG/Low Grade Glioma
- Neurofibromatosis Other
- Melanoma Relapse / Refractory
- Germ Cell Tumor New Diagnosis
- Germ Cell Tumor Relapse / Refractory
- All Other Solid Tumors
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
